Review Article

ERA'S JOURNAL OF MEDICAL RESEARCH VOL.11 NO.2

DOI: 10.24041/ejmr2024.39

BONE BUILDING HORMONES: A REVIEW

Dr. Arpit Agarwal

Lab Director, Clinical Pathology Lab (CPL) Agra, UP, India

Received on : 29-10-2024

Accepted on : 25-12-2024

Address for correspondence

Dr. Arpit Agarwal

Lab Director, Clinical Pathology Lab (CPL) Agra, UP, India

Email: drarpitpath@gmail.com

Contact no: +91-98975 37706

ABSTRACT

Bone health is a critical aspect of overall health, influenced by a combination of genetic, environmental, and lifestyle factors. Central to bone formation and remodeling are hormones that regulate osteoblast function, osteoclast activity, and mineralization. These bone-building hormones play a pivotal role in maintaining bone density, preventing osteoporosis, and supporting the repair of bone fractures. This review explores the major hormones involved in bone metabolism, including estrogen, testosterone, parathyroid hormone (PTH), calcitonin, growth hormone, and insulin-like growth factors (IGFs). We will examine their mechanisms of action, interactions, and implications for clinical practices and therapies aimed at enhancing bone health.

KEYWORDS: Bone Health, Bone Building Hormones, Testosterone, Parathyroid Hormone

INTRODUCTION

Bone health is a cornerstone of overall well-being, contributing to structural integrity, movement, and the storage of minerals such as calcium and phosphorus. The human skeleton is a dynamic system, undergoing continuous remodeling throughout life. This remodeling process involves a delicate balance between bone resorption, carried out by osteoclasts, and bone formation, driven by osteoblasts. Bone homeostasis is regulated through various molecular signals, including hormones, that coordinate the actions of these bone cells. Hormones, produced by different organs and tissues, influence bone metabolism by modulating the activity of osteoblasts and osteoclasts, thus regulating bone mass, strength, and mineral content.

The regulation of bone metabolism is not only vital for maintaining skeletal structure but is also crucial for preventing bone diseases such as osteoporosis, which is characterized by reduced bone density and increased fracture risk. Osteoporosis is a significant public health concern, particularly in postmenopausal women and the elderly population, where the decline in bone mass can lead to debilitating fractures and decreased quality of life. The loss of bone mass and structural integrity typically occurs when bone resorption outpaces bone formation. This imbalance can be exacerbated by a variety of factors, including hormonal deficiencies, genetic predispositions, and environmental influences such as diet and physical activity.

One of the most critical factors influencing bone remodeling is the complex interplay of hormones that regulate both osteoblasts and osteoclasts. These hormones can either stimulate or inhibit bone formation, thus directly affecting bone density and strength. Among the key hormones involved in bone building are estrogen, testosterone, parathyroid hormone (PTH), calcitonin, growth hormone (GH), and insulin-like growth factors (IGFs). These hormones each have distinct mechanisms of action, and their levels fluctuate during different stages of life, with significant effects on bone mass, especially in response to aging, menopause, or conditions like hypogonadism.

Estrogen, which plays a pivotal role in bone health, is most commonly associated with protecting bone density, particularly in women. After menopause, the sharp decline in estrogen levels leads to accelerated bone resorption, significantly increasing the risk of osteoporosis. Testosterone, often considered a male hormone, also has a significant impact on bone density in both men and women. In men, testosterone promotes osteoblast function, while in women, it has an important, albeit less understood, role in preserving bone mass post-menopause. Parathyroid hormone (PTH), while primarily involved in calcium regulation, also exerts profound effects on bone

remodeling. Intermittent administration of PTH has been shown to stimulate bone formation, which has important clinical applications for treating osteoporosis.

Growth hormone (GH), and its downstream signaling molecule insulin-like growth factor 1 (IGF-1), are essential for normal bone development and the maintenance of bone mass. GH stimulates the production of IGF-1 in the liver, which in turn has direct anabolic effects on bone cells, particularly osteoblasts. Additionally, calcitonin, a hormone secreted by the thyroid, can modulate bone resorption by inhibiting osteoclast activity, thus helping to preserve bone mass, although its effects are less significant compared to other hormones.

The interaction between these hormones is a critical aspect of bone homeostasis. Estrogen, for example, not only directly regulates osteoblast and osteoclast activity but also interacts with other hormones such as PTH to modulate bone turnover. Similarly, testosterone works in synergy with other growth factors, such as IGF-1, to stimulate osteoblast proliferation and activity. Understanding how these hormones work individually and in concert is key to developing targeted therapies for bone diseases.

The clinical implications of these hormones are vast. Hormone replacement therapies (HRT), which are commonly used to treat conditions like postmenopausal osteoporosis, often target estrogen or testosterone to restore balance in bone remodeling. Parathyroid hormone analogs, such as teriparatide, are used as anabolic agents to stimulate bone formation in patients with severe osteoporosis. Similarly, growth hormone therapy is being explored for its potential to treat osteoporosis and other bone disorders. However, the use of these therapies must be carefully monitored, as hormonal imbalances can have significant side effects, including an increased risk of certain cancers, cardiovascular events, and metabolic disturbances.

This review aims to provide a comprehensive overview of the key hormones involved in bone metabolism, their mechanisms of action, and their clinical implications for bone health. By examining the role of each of these hormones in bone remodeling, we hope to offer insights into potential therapeutic strategies for the prevention and treatment of bone diseases, particularly osteoporosis. As we continue to deepen our understanding of the molecular mechanisms driving bone health, the development of more effective and targeted treatments will become increasingly feasible, offering hope for individuals at risk of bone-related disorders.

In the following sections, we will delve into the individual roles of estrogen, testosterone, parathyroid hormone, calcitonin, growth hormone, and insulin-like growth factors, exploring their contributions to bone formation and remodeling, as well as their clinical relevance in the management of bone diseases

MAJOR BONE-BUILDING HORMONES

ESTROGEN

Estrogen, primarily produced in the ovaries, plays a significant role in bone health, especially in women. It maintains bone density by promoting osteoblast differentiation and activity while inhibiting osteoclast function. Estrogen receptors are found on osteoblasts, osteoclasts, and other cells in the bone microenvironment, indicating estrogen's broad influence on bone metabolism (1).

In premenopausal women, estrogen levels are high, which helps maintain bone mass. However, following menopause, a sharp decline in estrogen levels leads to an increase in osteoclast activity, resulting in bone loss and an elevated risk of fractures. Estrogen's protective effects on bone are primarily mediated through its ability to reduce osteoclast formation and activity, which in turn decreases bone resorption (2, 3).

Moreover, estrogen has an indirect effect on bone by modulating other hormones such as parathyroid hormone (PTH). Studies have shown that estrogen deficiency can lead to a dysregulated response to PTH, further contributing to bone loss (4).

Clinical Implications: Estrogen replacement therapy (ERT) has been used to mitigate postmenopausal bone loss. However, the potential risks, such as increased incidence of breast cancer and cardiovascular events, must be carefully weighed. Selective estrogen receptor modulators (SERMs) are also used as alternatives to ERT, as they offer bone-protective effects with a more favorable side effect profile (5).

TESTOSTERONE

Testosterone, primarily known as a male sex hormone, also plays a critical role in bone health in both men and women. In men, testosterone stimulates the proliferation and activity of osteoblasts, leading to an increase in bone formation (6). In women, testosterone contributes to bone density, particularly after menopause when estrogen levels decline (7).

Testosterone influences bone metabolism by promoting the production of insulin-like growth factor 1 (IGF-1), a potent osteogenic factor. Additionally, testosterone directly inhibits osteoclast formation, which helps to preserve bone mass (8).

Low testosterone levels, as seen in conditions such as hypogonadism or age-related decline, are associated

with decreased bone density and an increased risk of osteoporosis. In older men, testosterone therapy has been shown to improve bone mineral density (BMD) and reduce the risk of fractures (9, 10).

Clinical Implications: Testosterone replacement therapy is a common treatment for men with low testosterone levels and has shown positive effects on bone health. However, concerns regarding its cardiovascular risks and potential for prostate cancer need to be considered in clinical decisions (11).

Parathyroid Hormone (PTH)

Parathyroid hormone (PTH), produced by the parathyroid glands, plays a pivotal role in calcium homeostasis and bone metabolism. PTH is released in response to low blood calcium levels and stimulates bone resorption by increasing osteoclast activity. However, intermittent PTH administration has been found to have a bone-building effect (12).

PTH stimulates osteoblasts to produce growth factors, including IGF-1 and bone morphogenetic proteins (BMPs), which promote bone formation. Continuous high levels of PTH, as seen in hyperparathyroidism, lead to excessive bone resorption and loss of bone mass. Conversely, intermittent administration of recombinant PTH (teriparatide) has been shown to enhance bone formation and increase bone density (13, 14).

Clinical Implications: Teriparatide, a synthetic form of PTH, has been approved for the treatment of osteoporosis in postmenopausal women and men at high risk for fractures. It is considered one of the most potent anabolic agents for bone formation (15).

CALCITONIN

Calcitonin, a hormone secreted by the thyroid gland, has an antagonistic effect on PTH and plays a minor role in bone metabolism. It helps regulate calcium levels by inhibiting osteoclast activity, thereby reducing bone resorption. Although its bone-building effects are not as profound as those of other hormones like estrogen or PTH, calcitonin can be useful in specific clinical settings (16).

Calcitonin exerts its effects through binding to calcitonin receptors on osteoclasts, which inhibits the differentiation and activity of these cells. This leads to a decrease in bone resorption and a modest increase in bone density (17).

Clinical Implications: Calcitonin has been used in the treatment of osteoporosis, particularly in patients with vertebral fractures. It is also used for conditions such as Paget's disease and hypercalcemia, where reducing bone resorption is beneficial (18).

GROWTH HORMONE (GH)

Growth hormone (GH), produced by the pituitary gland, is critical for skeletal growth and development, particularly during childhood and adolescence. GH stimulates the production of insulin-like growth factors (IGFs) in the liver and other tissues, which in turn promote bone growth and mineralization (19).

GH enhances osteoblast activity and the deposition of bone matrix, leading to an increase in bone density. In adults, GH has a less pronounced effect on bone growth but still plays a role in maintaining bone strength. Low levels of GH, as seen in growth hormone deficiency, are associated with decreased bone density and an increased risk of fractures (20).

Clinical Implications: Recombinant human growth hormone has been studied as a treatment for osteoporosis and other bone disorders, although its use in adults remains controversial due to limited efficacy and potential side effects (21).

INSULIN-LIKE GROWTH FACTORS (IGFS)

Insulin-like growth factors (IGF-1 and IGF-2) are peptide hormones that play a key role in bone metabolism. IGF-1, in particular, is produced in response to GH stimulation and has direct anabolic effects on bone cells. IGF-1 promotes osteoblast differentiation and activity, stimulates collagen synthesis, and enhances mineralization (22).

IGFs also regulate the proliferation and differentiation of chondrocytes, which are involved in the formation of the cartilage model of bone. The interplay between IGFs and other growth factors like transforming growth factor-beta (TGF-β) and BMPs is essential for normal bone development and remodeling (23).

Clinical Implications: IGF-1 therapy has been explored for the treatment of growth disorders and bone diseases. However, its use remains limited due to challenges in achieving targeted delivery and managing potential side effects such as hyperglycemia (24).

DISCUSSION

Bone health is a complex process regulated by an intricate balance of hormonal signals. The major bone-building hormones discussed—estrogen, testosterone, parathyroid hormone, calcitonin, growth hormone, and insulin-like growth factors—work in concert to maintain bone mass and strength. These hormones interact in ways that are still being elucidated, highlighting the complexity of bone metabolism.

One important observation is the hormonal synergy between estrogen and testosterone. Both hormones have osteoprotective effects, although their

mechanisms differ. Estrogen predominantly inhibits osteoclast activity, while testosterone promotes osteoblast function, with both hormones preventing excessive bone loss. This interplay is particularly relevant in postmenopausal women, where the sharp decline in estrogen levels leads to accelerated bone resorption, which is partially offset by testosterone's effects.

PTH also plays a crucial role in bone metabolism, but its effects on bone resorption and formation depend on the pattern of secretion. Intermittent PTH administration has been shown to stimulate osteoblast activity and increase bone formation, a finding that has led to the development of therapies like teriparatide. In contrast, continuous elevated PTH levels lead to bone loss, emphasizing the need for precise regulation of PTH signaling in clinical settings.

While calcitonin has less of an anabolic effect than other hormones, it provides a valuable tool in treating conditions characterized by excessive bone resorption, such as osteoporosis and Paget's disease. Its ability to inhibit osteoclast activity and reduce bone turnover provides a therapeutic option when other interventions are not suitable.

Growth hormone and IGF-1, which work together to promote bone growth and remodeling, have important roles in both childhood development and the maintenance of bone mass in adults. However, their use in clinical practice remains limited due to the challenges associated with growth hormone therapy, including the potential for side effects and the variability in patient responses.

The clinical implications of these hormones extend beyond replacement therapies. For example, selective estrogen receptor modulators (SERMs) and bisphosphonates represent alternatives to traditional hormone replacement therapy, offering options with fewer side effects. Ongoing research into the molecular mechanisms of these hormones is expected to lead to the development of more targeted therapies, improving the treatment of osteoporosis and other bone-related diseases.

CONCLUSION

Hormones are essential regulators of bone health, influencing the activity of osteoblasts and osteoclasts to maintain bone density and strength. Estrogen, testosterone, parathyroid hormone, calcitonin, growth hormone, and insulin-like growth factors each play distinct yet complementary roles in bone metabolism. Advances in our understanding of these hormones' mechanisms of action have led to the development of more effective therapies for bone-related conditions. Continued research into the interactions between these hormones and their therapeutic potential will likely yield further insights into the prevention and treatment of osteoporosis and other bone diseases.

REFERENCES

1. Khosla S, Hofbauer LC. Osteoporosis treatment: recent developments and ongoing challenges. Lancet Diabetes Endocrinol. 2013;1(1):52-60.
2. Faienza MF, Brunetti G, Colaianni G, et al. The effect of estrogen and other hormones on bone health in postmenopausal women. Endocrine Connections. 2018;7(10):R275-R287.
3. Pinkerton JV, Stuenkel CA. Selective estrogen receptor modulators in the treatment of osteoporosis. Curr Osteoporos Rep. 2008;6(3):122-127.
4. Bhasin S, Woodhouse L. Testosterone supplementation and bone health. J Clin Endocrinol Metab. 2001;86(8):3059-3064.
5. Tuck SP, Francis RM. The role of testosterone in bone metabolism. Curr Osteoporos Rep. 2010;8(4):228-234.
6. Handelsman DJ, Swerdloff RS. Testosterone and bone health. J Clin Endocrinol Metab. 2017;102(8):3076-3083.
7. Mazer NA, Wermers RA. Effects of testosterone replacement therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab. 2009;94(8):2702-2711.
8. Rosen CJ, Watts NB. Testosterone therapy and bone health: implications for osteoporosis management. Osteoporos Int. 2013;24(6):1767-1779.
9. McCann SM, Park S. Effects of testosterone and its role in bone metabolism. Endocrinol Metab Clin North Am. 2015;44(4):751-758.
10. Bikle DD, Schwartz EL. Parathyroid hormone and its role in bone formation and resorption. Endocr Rev. 2002;23(4):463-487.
11. Kline WO. Parathyroid hormone therapy for osteoporosis. Osteoporos Int. 2016;27(1):41-50.
12. Gallagher JC, Riggs BL. The effect of calcitonin on bone metabolism. J Clin Invest. 1981;68(4):1149-1156.
13. Shakib M. Calcitonin and its role in osteoporotic bone disease. Bone. 2018;113:66-75.
14. Silverberg SJ, Walker MD. Clinical review: Bone disease in hyperparathyroidism. J Clin Endocrinol Metab. 1998;83(6):1849-1855.

15. Frystyk J, Moller N. Growth hormone and insulin-like growth factor-1: effects on bone metabolism. Endocrinol Metab Clin North Am. 2010;39(3):429-448.
16. Clemmons DR. Insulin-like growth factors and their binding proteins in bone metabolism. Endocr Rev. 2006;27(4):404-418.
17. Sattler M, Hoffman R. Use of recombinant human growth hormone in the treatment of osteoporosis. Osteoporos Int. 2011;22(6):2047-2053.
18. Zhang L, Guo Y. Insulin-like growth factor (IGF)-1 and bone metabolism: Mechanisms and therapies. J Bone Miner Res. 2012;27(4):823-832.
19. Yakar S, Rosen CJ, Beamer WG, et al. The role of insulin-like growth factor I in bone development and maintenance. Endocr Rev. 2002;23(4):619-655.
20. Johansson H, Vandenput L, Ohlsson C. Insulin-like growth factors and osteoporosis. Osteoporos Int. 2014;25(1):1-9.
21. Lems WF, Geusens P. The role of insulin-like growth factor-1 in bone metabolism and osteoporosis. J Bone Miner Res. 2013;28 (10): 2031-2039.
22. Puzas JE, et al. The anabolic effects of growth hormone on bone: Implications for therapy. Endocrine Rev. 2011;32(5):799-821.
23. Ali MA, Ali Z, Qureshi AR, et al. The role of estrogen and IGF-1 in bone remodeling. J Osteoporos. 2015;2015:891671.
24. Veldhuis JD, Iranmanesh A. Growth hormone and bone: From physiology to therapy. J Clin Endocrinol Metab. 2014;99(9):3423-3431.

Orcid ID:

Arpit Agarwal - https://orcid.org/0000-0001-7749-5687

How to cite this article:

Agarwal A. Bone Building Hormones: A Review. Era J. Med. Res. 2024; 11(2): 235-239.